An independent reference library on stem cell therapy and cancer immunotherapy — clinical research, mechanisms, and industry developments.
Step 1 — Topic
Step 2 — Category
MSC research for chronic pancreatitis: engineered-vesicle animal findings, two recruiting safety trials and why no approved treatment exists yet.
6 min readBy RegenMed Review Editorial Team · Medically Reviewed by the RegenMed Review Editorial Team
Read InvestigationPeptide therapy in Mexico: what clinics offer, the COFEPRIS and FDA regulatory picture, thin human evidence and what medical tourists should weigh.
By RegenMed Review Editorial Team · Medically Reviewed by the RegenMed Review Editorial Team
Read InvestigationEndocrine stem cell research compared: trial-stage islet therapy for type 1 diabetes versus preclinical thyroid, adrenal and PCOS programs.
By RegenMed Review Editorial Team · Medically Reviewed by the RegenMed Review Editorial Team
Read InvestigationGut health and aging: what digestion changes are normal, the microbiome-longevity link, fiber's evidence base and the fermented-foods trial.
By RegenMed Review Editorial Team · Medically Reviewed by the RegenMed Review Editorial Team
Read InvestigationChronic kidney disease explained: causes, silent symptoms, eGFR staging, standard care and where MSC research stands after the NEPHSTROM trial.
By RegenMed Review Editorial Team · Medically Reviewed by the RegenMed Review Editorial Team
Read Investigation
ASGCT’s May 4–8, 2027 meeting in Philadelphia: confirmed dates, expected scientific tracks, regulatory discussions and why the gathering matters for cell and gene therapy.
By RegenMed Review Editorial Team · Medically Reviewed by the RegenMed Review Editorial Team
Read Investigation
Surface markers, flow cytometry, CD34 and the ISCT’s minimal MSC identity criteria explained — including why research identity standards are not clinical release specifications.
By RegenMed Review Editorial Team · Medically Reviewed by the RegenMed Review Editorial Team
Read Investigation
